Domestic hyperlipidemia drug market in transition

The local hyperlipidemia drug market is undergoing a major transformation as Janssen’s Crestor (rosuvastatin)is likely to overtake Pfizer’s Lipitor (atorvastatin) in sales, reshuffling the leader board of a popular drug.

Lipitor kept its number 1 ranking in terms of revenue over the past years, but its monthly sales have been falling since the government-mandated cuts in drug prices in April...